Actimed Therapeutics secures £1.6m for muscle-wasting disorder research

The research and development of innovative pharmaceutical therapies for cancer cachexia and other muscle-wasting disorders is the primary focus of Actimed Therapeutics Ltd, which targets patients affected by these conditions. Based in Ascot, the company has raised an estimated £1.6m in its latest funding round, resulting in an estimated post-money valuation of £83.7m.

Incorporated in 2016, the firm is listed under the manufacturing sector on LinkedIn. Financial records for the year ending 31 December 2024 indicate a £4.1m loss. Staffing levels vary between reporting sources, with nine employees noted in the most recent accounts and 15 individuals listed on the platform.

The June 2026 filing follows a more substantial period in 2025, when £7.2m in total capital was secured. Online operations are managed via the website at actimedtherapeutics.com.